Free Trial

Annexon (ANNX) Projected to Post Earnings on Monday

Annexon logo with Medical background

Annexon (NASDAQ:ANNX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annexon Price Performance

Shares of NASDAQ ANNX traded down $0.10 during mid-day trading on Friday, reaching $1.61. 1,210,735 shares of the company's stock traded hands, compared to its average volume of 1,789,278. The business has a 50-day simple moving average of $2.00 and a 200 day simple moving average of $3.87. The stock has a market cap of $176.09 million, a P/E ratio of -1.53 and a beta of 1.24. Annexon has a 1-year low of $1.29 and a 1-year high of $7.85.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th.

Check Out Our Latest Research Report on ANNX

About Annexon

(Get Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Recommended Stories

Earnings History for Annexon (NASDAQ:ANNX)

Should You Invest $1,000 in Annexon Right Now?

Before you consider Annexon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.

While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines